tbuckley/cabot-search huggingface dataset:
Endometriosis-related ovarian cancer risk and prognosis: A meta-analysis.
Authors: S. Kang, H. Kim, J. W. Kim
Journal: Journal of Clinical Oncology (2011)

e15525 Background: The association between ovarian cancer and endometriosis has not been well established in previous studies. We investigated the impact of endometriosis on the development of ovarian cancer (OC) and prognosis in patients with OC using a meta-analysis. Methods: After we performed a MEDLINE search to identify all relevant studies between March 1945 and December 2010, we found 4 studies (2 case-control, 2 cohort; n=157,292) related with OC risk and 4 studies (1 case-control, 3 cohort; n=46,716) associated with prognosis in patients with OC among 2,402 potentially relevant studies. This meta-analysis was performed using the fixed-effect model because of no heterogeneity. Results: Endometriosis increased the risk of OC (RR, 1.25; 95% CI, 1.14-1.37). Although endometriosis did not influence the risk of OC in two cohort studies (RR, 1.30; 95% CI, 1.01-1.68), two case-control studies showed that endometriosis was associated with the increased of OC (RR, 1.24; 95% CI, 1.12-1.36). On the other hand, endometriosis-associated OC (EAOC) showed improved overall survival (OS) when compared with non-EAOC (HR, 0.77; 95% CI, 0.64-0.92). In sub-analyses based on the design of study, one case-control study demonstrated that EAOC was associated with improved OS (HR, 0.56; 95% CI, 0.36-0.87), and EAOC was also related with improved OS with marginal significance when compared with non-EAOC (HR, 0.82; 95% CI, 0.67-1.00) in three cohort studies. Conclusions: These findings suggest that women with endometriosis may have a higher risk of OC than those without endometriosis, whereas coexistent endometriosis may be associated with improved OS in patients with OC.
P2.06-043 3-Dimensional High Throughput Multi-Drug Screening Using Patient-Derived Tumor Cells (PDC) Established from Surgical Specimens of NSCLC
Authors: Sumin Shin, Yong Sung Shin, Hye Joo Choi, Jiryeon Jang, Jong Ho Cho, Hong Kwan Kim, Jeeyun Lee, Jhingook Kim
Journal: Journal of Thoracic Oncology (2017)
S34 Effect of 8 and 12 weeks’ once-daily tiotropium and olodaterol, alone and combined with exercise training, on exercise endurance during walking in patients with copd
Authors: T Troosters, J Bourbeau, F Maltais, N Leidy, D Erzen, D De Sousa, L Korducki, KL Lavoie, W Janssens, A Hamilton
Journal: Thorax (2016)

<h3>Rationale</h3> Physical deconditioning is common in patients with chronic obstructive pulmonary disease (COPD), limiting exercise tolerance. PHYSACTO<sup>®</sup> (NCT02085161) tested the effects of long-acting bronchodilators alone or combined with exercise training (ExT) on exercise endurance time (EET) in patients with COPD. All patients took part in a standardised physical activity self-management behaviour-modification (BM) programme. <h3>Methods</h3> A 12-week, randomised, partially double-blind, placebo-controlled, parallel-group trial at 34 sites in Australia, New Zealand, USA, Canada and Europe. Interventions (all with 12-week BM) were: BM + placebo; BM + tiotropium (T) 5 µg; BM + T + olodaterol (T/O) 5/5 µg; BM + T/O 5/5 µg with 8 weeks’ ExT (T/O 5/5 µg + ExT). EET (log transformed) during an endurance shuttle-walk test (ESWT) to symptom limitation was assessed after 8 weeks (primary end point) and 12 weeks. <h3>Results</h3> 303 patients (200 men) were randomised and treated (full analysis set n=274). Mean post-bronchodilator forced expiratory volume in 1 second was 1.59 L (57% predicted). EET was significantly increased in patients receiving BM + T/O 5/5 µg compared to placebo and was increased to a greater extent in patients receiving BM + T/O 5/5 µg + ExT compared to placebo at 8 weeks. EET was not significantly increased in patients receiving BM + T 5 µg compared to placebo (Table). Similar increases in EET were demonstrated at 12 weeks (Table). 13 patients reached test termination criteria (20 minutes) without symptom limitation (placebo, n=0; T, n=3; T/O, n=2; T/O + ExT, n=8) at 8 weeks. No safety concerns were identified. <h3>Conclusions</h3> When added to BM, the bronchodilator combination T/O 5/5 µg, used alone and combined with ExT, improved EET during ESWT compared to placebo in moderate to severe COPD. <h3>Funding</h3> Boehringer Ingelheim. Please refer to page A270 for declarations of interest in relation to abstract S34.
Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.
Authors: P Stopfer, HG Schaefer, A Amelsberg, H Huisman, F Eskens, Jourik Gietema, J Briscoe, N Lewis, RB Cohen, J Marshall, J Verweij
Journal: Clinical Cancer Research (2005)
P3.02b-037 Does Tissue EGFR Mutation Status Predict Treatment Response and Mortality in Adenocarcinoma Lung?
Authors: Anant Mohan, Ashutosh Dhanuka, Ashraf Ansari, Mirza Masroor, Kalpana Luthra, Alpana Saxena, Karan Madan, Vijay Hadda, G. Khilnani, Randeep Guleria
Journal: Journal of Thoracic Oncology (2017)
Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy
Authors: Nikoletta Lendvai, Sean Devlin, Minal Patel, Kristina Marie Knapp, Daniel Ekman, Ida Grundberg, David J Chung, Hani Hassoun, Guenther Koehne, Alexander M. Lesokhin, Heather Landau, Sergio A. Giralt, Neha S Korde, Ola Landgren
Journal: Blood (2015)
P2.02-054 Impact of Prognostic Nutrition Index for Induction Chemoradiotherapy Followed by Surgery in Locally Advanced Non-Small Lung Cancers
Authors: Junichi Soh, Shinichi Toyooka, Kazuhiko Shien, Hiromasa Yamamoto, Tsuyoshi Kurosaki, Kentaro Miyoshi, Shinji Otani, Seiichiro Sugimoto, Masaomi Yamane, Takahiro Oto, Susumu Kanazawa, Katsuyuki Kiura, Shinichiro Miyoshi
Journal: Journal of Thoracic Oncology (2017)
Killing colon cancer cells through PCD pathways by a novel hyaluronic acid-modified shell-core nanoparticle loaded with RIP3 in combination with chloroquine
Authors: Xueyan Hou, Chengli Yang, Lijing Zhang, Tingting Hu, Dan Sun, Hua Cao, Fan Yang, Gang Guo, Changyang Gong, Xiaoning Zhang, Aiping Tong, Rui Li, Yu Zheng
Journal: Biomaterials (2017)
Antithrombotic Therapy in Non-Neoplastic Chronic Portal Venous Thrombosis in Cirrhosis: Recanalization and Liver Function Evaluation,
Authors: Leyre Bento, Ana Rodriguez Huerta, Cristina Pascual, Gloria Pérez Rus, Vega Catalina, Ismael Yepes, Ana María Pérez-Corral, Javier Anguita, Mi Kwon, Jose Luis Diez Martin
Journal: Blood (2011)
Abstract 3554: Autophagy is Detrimental during Acute Phase but Protective during Chronic Phase after Myocardial Infarction
Authors: Shiori Kyoi, Hiromitsu Takagi, Nirmala Hariharan, Chiao-Po Hsu, Jonathan Galeotti, Tetsuro Ago, Peiyong Zhai, Beth Levine, Junichi Sadoshima
Journal: Circulation (2008)
Hemodynamic Support With a Microaxial Percutaneous Left Ventricular Assist Device (Impella) Protects Against Acute Kidney Injury in Patients Undergoing High-Risk Percutaneous Coronary Intervention
Authors: Michael P. Flaherty, Sadip Pant, Samir V. Patel, Tyler Kilgore, Sujith Dassanayaka, John H. Loughran, Wasiq Rawasia, Buddhadeb Dawn, Allen Cheng, Carlo R. Bartoli
Journal: Circulation Research (2017)

Acute kidney injury (AKI) is common during high-risk percutaneous coronary intervention (PCI), particularly in those with severely reduced left ventricular ejection fraction. The impact of partial hemodynamic support with a microaxial percutaneous left ventricular assist device (pLVAD) on renal function after high-risk PCI remains unknown.We tested the hypothesis that partial hemodynamic support with the Impella 2.5 microaxial pLVAD during high-risk PCI protected against AKI.In this retrospective, single-center study, we analyzed data from 230 patients (115 consecutive pLVAD-supported and 115 unsupported matched-controls) undergoing high-risk PCI with ejection fraction ≤35%. The primary outcome was incidence of in-hospital AKI according to AKI network criteria. Logistic regression analysis determined the predictors of AKI. Overall, 5.2% (6) of pLVAD-supported patients versus 27.8% (32) of unsupported control patients developed AKI (P<0.001). Similarly, 0.9% (1) versus 6.1% (7) required postprocedural hemodialysis (P<0.05). Microaxial pLVAD support during high-risk PCI was independently associated with a significant reduction in AKI (adjusted odds ratio, 0.13; 95% confidence intervals, 0.09-0.31; P<0.001). Despite preexisting CKD or a lower ejection fraction, pLVAD support protection against AKI persisted (adjusted odds ratio, 0.63; 95% confidence intervals, 0.25-0.83; P=0.04 and adjusted odds ratio, 0.16; 95% confidence intervals, 0.12-0.28; P<0.001, respectively).Impella 2.5 (pLVAD) support protected against AKI during high-risk PCI. This renal protective effect persisted despite the presence of underlying CKD and decreasing ejection fraction.
P1.08-060 Survival of Patients with Unsuspected N2 (Stage IIIA) Non-Small Cell Lung Cancer
Authors: Takashi Yamamichi, Masahiko Harada, Tsunekazu Hishima, Ayaka Asakawa, Masayuki Okui, Hirotoshi Horio
Journal: Journal of Thoracic Oncology (2017)
P1.03-017 Does PET/CT SUVmax Value Correlate with Long-Term Survival in Patients with Surgically Treated Stage I Non-Small Cell Lung Cancer
Authors: Huseyin Melek, Hasan Kara, Adalet Demir, Gamze Cetinkaya, Akif Turna, Ahmet Sami Bayram, Mehmet Erol, Alper Toker, Kamil Kaynak, Cengiz Gebitekin
Journal: Journal of Thoracic Oncology (2017)
P3.02b-063 Analysis of Survival in EGFR-Mutation-Positive Advanced Non-Small-Cell Lung Cancer Patients with Miliary Pulmonary Metastasis
Authors: Kageaki Watanabe, Yusuke Okuma, Maki Miwa, Yukio Hosomi, Tatsuru Okamura
Journal: Journal of Thoracic Oncology (2017)
On-going Mechanical Damage from Mastication Drives Homeostatic Th17 Cell Responses at the Oral Barrier
Authors: Nicolas Dutzan, Loreto Abusleme, Hayley Bridgeman, Teresa Greenwell-Wild, Tamsin Zangerle-Murray, Mark E. Fife, Nicolas Bouladoux, Holly Linley, Laurie Brenchley, Kelly Wemyss, Gloria Calderon, Bo-Young Hong, Timothy J. Break, Dawn M.E. Bowdish, Michail S. Lionakis, Simon A. Jones, Giorgio Trinchieri, Patricia I. Diaz, Yasmine Belkaid, Joanne E. Konkel, Niki M. Moutsopoulos
Journal: Immunity (2017)

Immuno-surveillance networks operating at barrier sites are tuned by local tissue cues to ensure effective immunity. Site-specific commensal bacteria provide key signals ensuring host defense in the skin and gut. However, how the oral microbiome and tissue-specific signals balance immunity and regulation at the gingiva, a key oral barrier, remains minimally explored. In contrast to the skin and gut, we demonstrate that gingiva-resident T helper 17 (Th17) cells developed via a commensal colonization-independent mechanism. Accumulation of Th17 cells at the gingiva was driven in response to the physiological barrier damage that occurs during mastication. Physiological mechanical damage, via induction of interleukin 6 (IL-6) from epithelial cells, tailored effector T cell function, promoting increases in gingival Th17 cell numbers. These data highlight that diverse tissue-specific mechanisms govern education of Th17 cell responses and demonstrate that mechanical damage helps define the immune tone of this important oral barrier.
Efficacy and Tolerability of Pregabalin in Decreasing Pain Associated with High Dose of Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase CML.
Authors: Francesco Iuliano, Massimo DI Maio, Stefania Infusino, Alessia Perricelli, Angelo Pomillo, Daniela Cilloni, Giuseppe Saglio
Journal: Blood (2007)
P3.02c-053 Clinical and Plasma Biomarkers for Disease Control with Nivolumab Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: Sameh Daher, Yaacov Lawrence, Elizabeth Dudnik, Ekaterina Hanovich, Damien Urban, Nir Peled, Rossie Navon, Raya Leibowitz-Amit, Ariel Hammerman, Erez Battat, Jair Bar, Amir Onn
Journal: Journal of Thoracic Oncology (2017)
P3.01-005 9 Year's in Oncopathology at a Latin American Country: Demographic and Pathology Characterization of Lung Cancer at National Cancer Institute
Authors: Silvia Josefina Ayala Leon, Miguel Antonio Aguero Pino, Miguel Ayala Leon, Cinthia Viviana Gauna Colás, Alicia Elizabeth Pomata Gunsett
Journal: Journal of Thoracic Oncology (2017)
Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma
Authors: Veronica Veschi, Zhihui Liu, Ty C. Voss, Laurent Ozbun, Berkley Gryder, Chunhua Yan, Ying Hu, Anqi Ma, Jian Jin, Sharlyn J. Mazur, Norris Lam, Barbara K. Souza, Giuseppe Giannini, Gordon L. Hager, Cheryl H. Arrowsmith, Javed Khan, Ettore Appella, Carol J. Thiele
Journal: Cancer Cell (2017)
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience
Authors: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, Andrzej Niemierko, Michael Drumm, Niall M. Heney, Marc D. Michaelson, Richard J. Lee, Philip J. Saylor, Matthew F. Wszolek, Adam S. Feldman, Douglas M. Dahl, Anthony L. Zietman, Jason A. Efstathiou
Journal: European Urology (2017)
Response to Imatinib or Imatinib Containing Regimens of Secondary Clones in Chronic Myeloid Leukemia Patients with Additional Chromosomal Abnormalities.
Authors: Debora Luzi, Lorenzo Falchi, Giovanna Rege Cambrin, Emilia Giugliano, Monica Schippa, Viola Festuccia, Ilaria Angeletti, Emilio Donti, Anna Marina Liberati
Journal: Blood (2007)
Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia
Authors: Steven Goossens, Sofie Peirs, Wouter Van Loocke, Jueqiong Wang, Mina Takawy, Filip Matthijssens, Stefan E. Sonderegger, Katharina Haigh, Thao Nguyen, Niels Vandamme, Magdaline Costa, Catherine Carmichael, Filip Van Nieuwerburgh, Dieter Deforce, Oded Kleifeld, David J. Curtis, Geert Berx, Pieter Van Vlierberghe, Jody J. Haigh
Journal: Blood (2017)
Examination of ALAS2, ABC7, Rag1, and IL6 Genes as Candidate Modifiers of Iron Overload in HFE C282Y Homozygotes with Severe Iron Overload.
Authors: Pauline L. Lee, James C. Barton, Carol West, Karen Crain, Sreenivas V. Rao, Ernest Beutler
Journal: Blood (2005)
S114 Predictors of primary treatment failure in children with empyema
Authors: ES Ward-Booth, DA Spencer, JY Paton, SP Rushton, M Brodlie, MF Thomas
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Empyema is a relatively rare but severe form of respiratory infection in childhood associated with significant morbidity. A decade long prospective observational study of paediatric empyema – the UK-ESPE study – completed recruitment in April 2016. This preliminary analysis focused on identification of predictors of primary treatment failure. <h3>Methods</h3> Data were available from 23 UK centres on 542 patients aged 0–16 years, admitted between December 2006 to December 2015, who were diagnosed with empyema and required pleural drainage. A standard logistic regression approach was used to evaluate the influence of age, sex, pre-hospital illness length, total illness length, time from admission to pleural drainage, length of pleural drainage, length of hospital stay, primary treatment modality and co-morbidity on the risk of primary treatment failure. Variables were investigated using univariate analysis and those that were significant were included in a multivariate model. Stepwise removal was then used to generate a parsimonious final multivariate model. The primary outcome measure was treatment failure as defined by a second procedure carried out &gt;24 hours after the primary pleural drainage procedure. <h3>Results</h3> The study group was 56% male, median age was 4 years (IQR 2–7). Recorded pre-hospital illness length was a median of 7 days (IQR 4–10) and total hospital length of stay 12 days (IQR 9–16). 34.7% of children had a co-morbidity recorded. Baseline characteristics were similar in children who did (n = 37) or did not fail (n = 505) primary treatment. There was substantial variation in the choice of primary treatment; chest drainage alone (20.1%), chest drainage with fibrinolytics (58.4%), video-assisted thoracoscopic surgery (12.1%), decortication (8.9%) and other treatments (0.3%). Treatment failure occurred in 6.9% of children and no demographic factor was found to influence treatment failure. The only significant predictor of treatment failure was primary method of treatment (Table). The relative risk of treatment failure was highest in children who received chest drainage alone (OR = 3.04 (95% CI: 1.47–6.27)). <h3>Conclusions</h3> In this large cohort no predictors of treatment failure other than primary treatment modality were identified and those who had chest drainage alone had the highest risk of failure.
Socioeconomic Inequalities in Body Mass Index across Adulthood: Coordinated Analyses of Individual Participant Data from Three British Birth Cohort Studies Initiated in 1946, 1958 and 1970
Authors: David Bann, William Johnson, Leah Li, Diana Kuh, Rebecca Hardy
Journal: PLoS Medicine (2017)

High body mass index (BMI) is an important contributor to the global burden of ill-health and health inequality. Lower socioeconomic position (SEP) in both childhood and adulthood is associated with higher adult BMI, but how these associations have changed across time is poorly understood. We used longitudinal data to examine how childhood and adult SEP relates to BMI across adulthood in three national British birth cohorts.The sample comprised up to 22,810 participants with 77,115 BMI observations in the 1946 MRC National Survey of Health and Development (ages 20 to 60-64), the 1958 National Child Development Study (ages 23 to 50), and the 1970 British Cohort Study (ages 26 to 42). Harmonized social class-based SEP data (Registrar General's Social Class) was ascertained in childhood (father's class at 10/11 y) and adulthood (42/43 years), and BMI repeatedly across adulthood, spanning 1966 to 2012. Associations between SEP and BMI were examined using linear regression and multilevel models. Lower childhood SEP was associated with higher adult BMI in both genders, and differences were typically larger at older ages and similar in magnitude in each cohort. The strength of association between adult SEP and BMI did not vary with age in any consistent pattern in these cohorts, but were more evident in women than men, and inequalities were larger among women in the 1970 cohort compared with earlier-born cohorts. For example, mean differences in BMI at 42/43 y amongst women in the lowest compared with highest social class were 2.0 kg/m2 (95% CI: -0.1, 4.0) in the 1946 NSHD, 2.3 kg/m2 (1.1, 3.4) in the 1958 NCDS, and 3.9 kg/m2 (2.3, 5.4) the in the 1970 BCS; mean (SD) BMI in the highest and lowest social classes were as follows: 24.9 (0.8) versus 26.8 (0.7) in the 1946 NSHD, 24.2 (0.4) versus 26.5 (0.4) in the 1958 NCDS, and 24.2 (0.3) versus 28.1 (0.8) in the 1970 BCS. Findings did not differ whether using overweight or obesity as an outcome. Limitations of this work include the use of social class as the sole indicator of SEP-while it was available in each cohort in both childhood and adulthood, trends in BMI inequalities may differ according to other dimensions of SEP such as education or income. Although harmonized data were used to aid inferences about birth cohort differences in BMI inequality, differences in other factors may have also contributed to findings-for example, differences in missing data.Given these persisting inequalities and their public health implications, new and effective policies to reduce inequalities in adult BMI that tackle inequality with respect to both childhood and adult SEP are urgently required.
P2.02-026 Individualized Adjuvant Chemotherapy for Resected Lung Cancer According to Collagen Gel Droplet-Embedded Culture Drug Sensitivity Test
Authors: Masayoshi Inoue, Hajime Maeda, Yukiyasu Takeuchi, Kenjiro Fukuhara, Yasushi Shintani, Yasunobu Funakoshi, Soichiro Funaki, Takashi Nojiri, Takashi Kusu, Hidenori Kusumoto, Toru Kimura, Meinoshin Okumura
Journal: Journal of Thoracic Oncology (2017)
Early Molecular Response to Imatinib in CP-CML Patients: The Significance of Early Dose Intensity and OCT-1 Activity in Responders and Efficacy of Dose Escalation and Switch to Nilotinib in Non-Responders
Authors: Deborah L. White, Verity A Saunders, David T Yeung, Andrew Grigg, Timothy P. Hughes
Journal: Blood (2012)
MA02.02 A Novel 5-miR Signature Shows Promise as a Diagnostic Tool and as a Predictor of Cisplatin Response in NSCLC
Authors: Lauren Mac Donagh, Steven Gray, Sinead Cuffe, Stephen Finn, Niamh Fitzgerald, Vincent Young, Ronan Ryan, Siobhan Nicholson, Niamh Leonard, Kenneth O’Byrne, Martin Barr
Journal: Journal of Thoracic Oncology (2017)
Comparison of Survival Outcomes Among Human Papillomavirus–Negative cT1-2 N1-2b Patients With Oropharyngeal Squamous Cell Cancer Treated With Upfront Surgery vs Definitive Chemoradiation Therapy
Authors: Jacqueline R. Kelly, Henry S. Park, Yi An, Joseph N. Contessa, Wendell G. Yarbrough, Barbara A. Burtness, Roy Decker, Zain Husain
Journal: JAMA Oncology (2017)

Human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) has shown resistance to conventional concurrent chemoradiation (CRT) therapy and carries a relatively poor prognosis in comparison with HPV-positive disease, with decreased locoregional control and overall survival (OS). In the present analysis, we examine whether upfront surgical resection improves overall survival in a large national sample.To compare survival outcomes among patients with newly diagnosed cT1-2 N1-2b HPV-negative OPSCC when treated with primary surgical resection vs CRT.This was an observational study of factors associated with primary treatment modality were identified using multivariable logistic regression. Overall survival was compared using Kaplan-Meier analysis with log-rank tests, multivariable Cox regression, and propensity score matching. Statistical tests were 2-sided. Patients newly diagnosed as having cT1-2 N1-2b pathologically confirmed HPV-negative OPSCC in 2010 to 2012 were identified using the National Cancer Data Base, which includes more than 70% of patients newly diagnosed as having cancer in the United States.Primary surgical resection vs definitive CRT.Overall survival.We identified 1044 patients, among whom 460 (44.1%) received upfront surgery and 584 (55.9%) received CRT. Median age was 59 years (range, 25-90 years); 812 patients were male (77.8%), 232 were female (22.2%). Median follow-up was 30 months. Approximately 59% of surgical patients received adjuvant CRT. On multivariable Cox regression, upfront surgery was not associated with increased OS when compared with CRT (adjusted hazard ratio [HR], 1.01; 95% CI, 0.74-1.39; P = .93). Propensity score-matching identified a cohort of 822 patients and redemonstrated equivalent OS (HR, 1.14; 95% CI, 0.81-1.62; P = .46). Lack of OS benefit with upfront surgery persisted in a subset analysis of patients with margin-negative resection (HR, 0.97; 95% CI, 0.66-1.45; P = .88).In this observational study, OS was similar for patients with HPV-negative OPSCC when treated with primary surgery vs CRT. Most surgical patients received trimodal therapy with adjuvant CRT. Our data may have implications for future research focusing on optimal patient selection for surgery.